Funder
Taipei Medical University–Wan Fang Hospital
Ministry of Science and Technology, Taiwan
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Zappa, C., & Mousa, S. A. (2016). Non-small cell lung cancer: Current treatment and future advances. Translational Lung Cancer Research, 5(3), 288–300.
2. Guo, K., et al. (2015). Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. OncoTargets and Therapy, 8, 3289–3296.
3. Stewart, E. L., Tan, S. Z., Liu, G., & Tsao, M. S. (2015). Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Translational Lung Cancer Research, 1, 67–81.
4. Xu, J., et al. (2016). EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. Scientific Reports, 6, 36371.
5. Wu, D., Xie, J., Dai, H. & & Fang, W. (2022). Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation. BMC Health Services Research, 22(1), 431